PubRank

Massimo F Martelli

Author PubWeight™ 103.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002 12.75
2 Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005 12.18
3 Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011 4.57
4 Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008 4.26
5 Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005 3.90
6 Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005 3.81
7 Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007 3.32
8 Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2006 2.68
9 Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006 2.06
10 A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008 1.94
11 NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 2010 1.80
12 NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002 1.63
13 Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005 1.54
14 Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006 1.41
15 Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011 1.40
16 Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 2006 1.34
17 Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005 1.33
18 Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 2007 1.27
19 A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol 2009 1.26
20 Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev 2012 1.24
21 CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 2010 1.21
22 Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005 1.14
23 NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 2007 1.11
24 Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008 1.07
25 Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2007 1.06
26 The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 2005 0.97
27 Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. Best Pract Res Clin Haematol 2011 0.97
28 Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J 2004 0.96
29 Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007 0.95
30 Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation. Blood Cells Mol Dis 2004 0.94
31 Natural killer cell alloreactivity for leukemia therapy. J Immunother 2005 0.92
32 Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. Semin Oncol 2012 0.91
33 Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol 2006 0.91
34 Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood 2002 0.90
35 Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction. Eur J Immunol 2012 0.90
36 The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2007 0.90
37 A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica 2008 0.89
38 Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol 2014 0.89
39 Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha. Blood 2004 0.87
40 The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 2005 0.87
41 From 'megadose' haploidentical hematopoietic stem cell transplants in acute leukemia to tolerance induction in organ transplantation. Blood Cells Mol Dis 2007 0.86
42 Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica 2008 0.85
43 Typical genomic imbalances in primary MALT lymphoma of the orbit. J Pathol 2003 0.85
44 Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann N Y Acad Sci 2003 0.84
45 Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol 2006 0.84
46 High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma. Hematology 2012 0.83
47 Human homeobox gene HOXC13 is the partner of NUP98 in adult acute myeloid leukemia with t(11;12)(p15;q13). Genes Chromosomes Cancer 2003 0.83
48 Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann N Y Acad Sci 2005 0.83
49 The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. Blood 2013 0.82
50 Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Int J Hematol 2005 0.82
51 T regulatory cell separation for clinical application. Transfus Apher Sci 2012 0.82
52 Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol 2008 0.82
53 Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases. Springer Semin Immunopathol 2004 0.82
54 e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Haematologica 2005 0.82
55 Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8-10, 2004. Blood Cells Mol Dis 2004 0.80
56 Cryptic insertion producing two NUP98/NSD1 chimeric transcripts in adult refractory anemia with an excess of blasts. Genes Chromosomes Cancer 2004 0.80
57 Hematopoietic stem cell transplantation from alternative sources in adults with high-risk acute leukemia. Blood Cells Mol Dis 2004 0.80
58 Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis 2004 0.80
59 High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med 2011 0.79
60 t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemia. Haematologica 2008 0.79
61 Philadelphia-positive acute lymphoblastic leukemia with multiple subclones including duplication of the Philadelphia chromosome and Abelson oncogene. Cancer Genet Cytogenet 2002 0.79
62 A NUP98-positive acute myeloid leukemia with a t(11;12)(p15;q13) without HOXC cluster gene involvement. Cancer Genet Cytogenet 2009 0.78
63 Dual-color split signal fluorescence in situ hybridization assays for the detection of CALM/AF10 in t(10;11)(p13;q14-q21)-positive acute leukemia. Haematologica 2006 0.78
64 Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option. Curr Stem Cell Res Ther 2007 0.78
65 Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia. Cancer Genet Cytogenet 2007 0.77
66 Chronic lymphocytic leukaemia Is terminal del(14)(q24) a new marker for prognostic stratification? Leuk Res 2006 0.77
67 The importance of bone marrow transplantation for patients who do not have a matched sibling donor. Best Pract Res Clin Haematol 2011 0.75
68 Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment. Hum Gene Ther 2005 0.75
69 Large-scale generation of human allodepleted anti-3rd party lymphocytes. Blood Cells Mol Dis 2007 0.75
70 Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. Biol Blood Marrow Transplant 2006 0.75
71 Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation. Hum Immunol 2005 0.75
72 Interpretation of the complex karyotype and identification of a new 6p amplicon by integrated comparative genomic hybridization and fluorescence in situ hybridization on the U937-I cell line. Cancer Genet Cytogenet 2002 0.75
73 Thymosin alpha1 to harness immunity to pathogens after haploidentical hematopoietic transplantation. Ann N Y Acad Sci 2010 0.75
74 Different mechanisms lead to a karyotypically identical t(20;21) in myelodysplastic syndrome and in acute myelocytic leukemia. Cancer Genet Cytogenet 2003 0.75
75 Crossing the HLA barriers. Blood Cells Mol Dis 2004 0.75
76 Natural killer cells as a therapeutic tool in mismatched transplantation. Best Pract Res Clin Haematol 2004 0.75